Erasca
ERAS
14.12
-0.18
-1.26%
Erasca
US · ERAS
#2103 by market cap
Listed 2021
14.12
-0.18
-1.26%
Live - 5344 symbols - heartbeat 431s ago
· 2026-10-08 04:33
Pre-market
14.08
-0.28%
After-hours
14.12
0.00%
- Market cap
- 4.94B
- P/E (TTM)i
- -14.86
- P/Bi
- 13.64
- EPSi
- -0.44
- Div yieldi
- 0.00%
- 52W posi
- 54%
Reader sentiment
Are you bullish or bearish on ERAS?
Anonymous reader poll. Unscientific, not investment advice.
About Erasca
Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.
- Founded
- 2018
- CEO
- Dr. Jonathan E. Lim,M.D.
- Employees
- 103
- Headquarters
- San Diego, California, United States of America
- Fiscal year end
- 12-31
- Website
- erasca.com
Company profile
- Exchange
- US
- Symbol
- ERAS
- Market-cap rank
- #2103
- Listing date
- 2021-07-16
- Market cap
- 4.94B
- Float cap
- 3.60B
- Shares out
- 349.76M
- Float shares
- 255.21M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 04:33:12 · For reference only, not investment advice and not tailored to your situation.